文献速递免疫规划

在意大利开展的一项开放标签、对照、多中心试验:对10年前按3、5、11月龄程序接种六价疫苗的健康儿童给予乙肝疫苗激发剂量的安全性和免疫应答

Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
PubMed 文献 · Vaccine · 2017-06-16

这项在意大利开展的开放标签、对照、多中心试验纳入751名健康青少年(11-13岁),他们婴儿期按3、5、11月龄程序接种过Hexavac或Infanrix hexa。所有受试者接受单价乙肝疫苗HBVaxPro 5µg激发剂量,激发后1个月Hexavac队列83.6%(95%CI 79.6; 87.1)、Infanrix hexa队列96.4%(95%CI 93.8; 98.1)抗-HBs≥10mIU/mL;两组均未观察到活动性乙肝疾病,激发剂量耐受良好。

要点

  • 激发后1个月抗-HBs≥10mIU/mL:Hexavac队列83.6%(95%CI 79.6; 87.1),Infanrix hexa队列96.4%(95%CI 93.8; 98.1)。
  • 激发前抗-HBs≥10mIU/mL:Hexavac队列23.9%(95%CI 19.7; 28.4),Infanrix hexa队列69%(95%CI 63.8; 74.0)。
  • 激发前抗-HBs<10mIU/mL者中,Hexavac队列78.7%(95%CI 73.6; 83.2)、Infanrix hexa队列88.5%(95%CI 80.7; 93.9)达到保护性抗体浓度。

核心结论

  • 这些数据证实,在采用两剂基础免疫加一剂加强的六价疫苗(Hexavac或Infanrix hexa)接种程序后至少10年,高比例儿童(>80%)仍存在免疫记忆。

研究设计与样本

  • 开放标签、对照、多中心试验,在意大利纳入751名健康青少年(11-13岁),婴儿期按3、5、11月龄程序接种Hexavac(n=409)或Infanrix hexa(n=342)。
  • 所有参与者接受单价乙肝疫苗HBVaxPro 5µg激发剂量,激发前和激发后1个月测量抗-HBs浓度。
  • 分析为描述性,未检验正式假设。

主要发现

  • 激发后1个月,Hexavac队列331名参与者抗-HBs≥10mIU/mL(83.6%,95%CI 79.6; 87.1),Infanrix hexa队列324名(96.4%,95%CI 93.8; 98.1)。
  • 激发前,Hexavac队列94名儿童抗-HBs≥10mIU/mL(23.9%,95%CI 19.7; 28.4),Infanrix hexa队列232名(69%,95%CI 63.8; 74.0)。
  • 激发前抗-HBs<10mIU/mL者中,Hexavac队列236名(78.7%,95%CI 73.6; 83.2)、Infanrix hexa队列92名(88.5%,95%CI 80.7; 93.9)达到保护性抗-HBs抗体浓度。
  • 两组均未观察到活动性乙肝疾病的证据,HBVaxPro激发剂量耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The strategy of vaccinating infants to prevent hepatitis B virus infection in adolescence or adulthood requires durable immunity. This study investigated responses to a challenge dose of monovalent hepatitis B vaccine in children primed with three doses of either Hexavac® or Infanrix hexa® 10years earlier during infancy. METHODS: This open-label, controlled, multicentre study conducted in Italy, enrolled 751 healthy pre-adolescents (aged 11-13years) who were given either Hexavac (n=409) or Infanrix hexa (n=342) at 3, 5 and 11months of life. All participants received a challenge dose of a monovalent hepatitis B vaccine (HBVaxPro® 5µg). The concentrations of antibodies to hepatitis B surface antigen (anti-HBs) were measured before and 1month after the challenge dose. The analysis was descriptive and no formal hypothesis was tested. RESULTS: One month post-challenge, 331 participants in the Hexavac cohort [83.6%, 95% CI: 79.6; 87.1] and 324 in the Infanrix hexa cohort [96.4%, 95% CI: 93.8; 98.1] had anti-HBs concentrations ≥10mIU/mL. Before the challenge dose, an anti-HBs concentration of ≥10mIU/mL was found in 94 children in the Hexavac cohort [23.9%, 95% CI: 19.7; 28.4] and in 232 children in the Infanrix hexa cohort [69%, 95% CI: 63.8; 74.0]. Among children with a pre-challenge anti-HBs concentration of <10mIU/mL, 236 [78.7%, 95% CI: 73.6; 83.2] in the Hexavac cohort and 92 [88.5%, 95% CI: 80.7; 93.9] in the Infanrix hexa cohort achieved protective anti-HBs antibody concentrations. No evidence of active hepatitis B disease was observed in either group, and the HBVaxPro challenge dose was well tolerated. CONCLUSIONS: These data confirm that immune memory persists in a high percentage of children (>80%) at least 10years after a two-dose primary and booster vaccination schedule with a hexavalent vaccine (Hexavac or Infanrix hexa). TRIAL REGISTRATION: EudraCT Number: 2013-001602-28; clinicaltrials.gov: NCT02012998.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zanetti A, Desole MG, Romanò L, et al. Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy. Vaccine. 2017. PMID: 28624307. doi:10.1016/j.vaccine.2017.05.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。